Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors

Area of Science:

• Molecular Biology
• Cell Signaling
• Cancer Research

Background:

• RAF proteins (BRAF, CRAF) are key regulators of the MAPK/ERK pathway, crucial in cell proliferation and survival.
• BRAF inhibitors like vemurafenib and dabrafenib are used to treat BRAF-mutant cancers but can paradoxically activate wild-type RAF signaling.
• Understanding RAF dimerization and drug-specific effects is vital for targeted cancer therapy.

Purpose of the Study:

• To investigate the effects of BRAF inhibitors on RAF homo- and heterodimer signaling using a novel optogenetic tool.
• To elucidate the mechanisms behind paradoxical activation of RAF signaling by BRAF inhibitors.
• To differentiate the effects of vemurafenib and dabrafenib on RAF signaling dynamics.

Main Methods:

• Development and application of optoRAF, an optogenetic tool for light-induced RAF protein clustering and activation.
• Utilizing optoRAF to mimic RAS-mediated RAF dimerization and study BRAF/CRAF homo- and heterodimer signaling.
• Treatment of cells with vemurafenib and dabrafenib to assess their impact on light-stimulated RAF signaling and protein levels.

Main Results:

• Vemurafenib paradoxically activated BRAF and CRAF homo- and heterodimers.
• Dabrafenib showed dose-dependent effects: enhancing CRAF activity at low doses and inhibiting it at high doses.
• Dabrafenib increased CRAF protein levels, leading to elevated RAF signaling independently of light activation.

Conclusions:

• OptoRAF is a powerful tool for dissecting RAF signaling pathways and drug-specific effects.
• BRAF inhibitors exhibit complex, context-dependent effects on RAF signaling, including paradoxical activation and protein level modulation.
• Findings highlight the differential mechanisms of vemurafenib and dabrafenib, informing future therapeutic strategies.